{"id":430595,"date":"2021-02-08T08:33:40","date_gmt":"2021-02-08T13:33:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=430595"},"modified":"2021-02-08T08:33:40","modified_gmt":"2021-02-08T13:33:40","slug":"ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/","title":{"rendered":"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin"},"content":{"rendered":"
\n

Rapha Capital Management Leads Convertible Note Financing<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MIAMI<\/span>, Feb. 8, 2021<\/span> \/PRNewswire\/ — Ponce Therapeutics, Inc. (“Ponce”), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, has now become operational with the launching of its first R & D program, targeting aging-associated skin disorders. The Company has secured laboratory space in Houston, TX<\/span>, and has hired its first scientists for executing their R & D plan targeting the elimination of p16-expressing cells in the skin. The cell proliferation inhibitor, p16, is highly expressed in both senescent cells and in in situ<\/i> carcinoma (Bowen’s Disease), which will be the focus of Ponce’s efforts for first product approval.<\/p>\n

\n

\n
\n \"Ponce
\n <\/a>\n <\/p>\n<\/p><\/div>\n

Rapha Capital Management, LLC (https:\/\/www.raphacap.com<\/a>), an investment management firm located in Miami, Florida<\/span>, through Rapha Capital Investment XIII, LLC (“RCI XIII”) (an entity managed by Rapha Capital), led Ponce’s recently closed Convertible Note financing.\u00a0 The $1,500,000<\/span> financing will be used to transition Ponce into an operational company and begin execution of Ponce’s R & D plan.\u00a0 With the close of the Convertible Note financing, Kevin Slawin<\/span>, founder and President of Rapha Capital Management, added the title of Executive Chairman, to his CEO role at Ponce.<\/p>\n

Rapha Capital is an investment management firm focused on making strategic investments in early stage, non-public biotechnology companies, through special purpose joint venture entities which it manages.\u00a0 Rapha Capital was founded by its President, Kevin Slawin<\/span>, M.D., a successful and experienced oncologic and robotic surgeon.\u00a0 After leaving practice, Dr. Slawin has been serving as a biotech consultant, investor, and founder, focusing on disruptive technologies in oncology, T cells and immunotherapy, and other breakthrough healthcare technologies.\u00a0 He is the founder of Bellicum Pharmaceuticals, Inc.<\/a>\u00a0(“Bellicum”), a publicly traded company listed on NASDAQ, leading Bellicum to a successful $161 million<\/span> IPO in December, 2014. \u00a0He also plays a guiding role in several of the investments managed by Rapha Capital in certain companies, serving as a board member at 3DBio Therapeutics, Inc. (https:\/\/3dbiocorp.com\/<\/a>), FIZE Medical, Inc. (www.fizemedical.com<\/a>), and Demeetra AgBio, Inc. (www.demeetra.com<\/a>).<\/p>\n

\n Kevin Slawin<\/span>, MD is the founder of Ponce, and will serve as the Chairman and CEO.\u00a0 David Spencer<\/span>, PhD. is the founding Chief Technology Officer.\u00a0 Ponce Therapeutics, Inc. reunites the team that founded Bellicum Pharmaceuticals and took it public in 2014 with a $55 million<\/span> crossover Series C and a $161 million<\/span> IPO. The team is retooling their original cell control technology with state-of-the-art advances towards their new goal of creating anti-aging products with a solid underlying scientific basis that actually work.<\/p>\n

“The science of aging has continued to mature and can now provide a scientific basis for technologies to reverse the aging process in humans.\u00a0 Proof of concept data in animal models demonstrates that removal of senescent cells from organs improves their function and imbues them with a more youthful profile.\u00a0 Targeting p16-expressing cells for apoptotic elimination is one approach to removing senescent cells from the body and is also a valid approach to targeting Bowen’s disease of the skin, which also expresses high levels of p16, profile,” said Dr. Slawin.\u00a0 “I’m excited to begin work in the anti-aging space, which I believe will quickly rival oncology in both value and interest” he added. “Given our greater than two-decade animal model and clinical experience with regulated cell signaling and cell survival, along with recent advances in non-viral gene delivery platforms, we are now poised to leverage an increasingly detailed, mechanistic understanding of aging to arrest or even reverse it,” added Dr. Spencer.<\/p>\n

\n A<\/b>
\n bout Rapha Capital Management, LLC<\/b> \u2013 \u00a0Rapha Capital Management, LLC<\/a> is an investment management firm located in Miami, Florida<\/span>, focusing on strategic investments in early stage, non-public biotechnology companies.\u00a0 Rapha Capital was founded by its President, Kevin Slawin<\/span>, MD, a successful and experienced oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on technologies in oncology, T cells and immunotherapy, as well as other breakthrough<\/span>healthcare technologies.\u00a0 He is the founder of Bellicum Pharmaceuticals, Inc.<\/a> (NASDAQ: BLCM).\u00a0 He is co-Inventor of the FDA,<\/span>-approved “prostate health index (phi)” <\/a><\/i>test licensed and marketed by Beckman Coulter<\/span> and utilized around the world.\u00a0 He has published extensively in top medical and scientific journals including the\u00a0Journal of the American Medical Association (JAMA)<\/i><\/b>, Journal of the National Cancer Institute (JNCI)<\/i><\/b>, and the New England Journal of Medicine (NEJM)<\/i><\/b>.\u00a0 <\/i>He has also been routinely listed in America’s Top Doctors for Cancer<\/i> (Castle Connolly Medical) and The Best Doctors in America<\/i> (Woodward\/White).\u00a0 In 2003, he was awarded the F. Brantley Scott, Jr.<\/span>, Award for Innovation and Creativity in Urology.<\/b><\/p>\n

\n About Ponce Therapeutics, Inc.
<\/b>Ponce Therapeutics \u2013 “Anti-aging Technologies Based on Real Science and Developed by Real Scientists<\/i>” – Ponce Therapeutics is leveraging the growing scientific knowledge surrounding the process of aging to develop its first state-of-the-art biotechnology platform to restore the youthful balance of aged or “senescent” and young cells in the skin, targeting the p16-expressing senescent cells for elimination. This provides a “reboot” of one’s genetic program to turn the clock on one’s skin back to its youthful exuberance.\u00a0 Targeting p16 will also potentially allow targeting of Bowen’s disease as the regulatory pathway for approval.\u00a0 While initially focused on skin, Ponce is planning to develop a wide-ranging portfolio of anti-aging products based on the best science in the nascent anti-aging field. Ponce\u00a0is headquartered in Miami, Florida<\/span> with research facilities located in Houston, TX.<\/span> For more information, visit\u00a0www.poncethera.com<\/a>\u00a0or email info@poncethera.com<\/a>. <\/p>\n

For more information about Ponce Therapeutics, Inc., email info@poncethera.com<\/a> or visit https:\/\/www.poncethera.com<\/a><\/p>\n

For more information about Rapha Capital Management, email info@raphacapital.com<\/a>\u00a0or visit https:\/\/www.raphacap.com<\/a><\/p>\n

\n

\n
\n \"(PRNewsfoto\/Rapha
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n \"Cision\" View original content to download multimedia:http:\/\/www.prnewswire.com\/news-releases\/ponce-therapeutics-inc-commences-first-r–d-program-in-anti-aging-products-for-skin-301221629.html<\/a><\/p>\n

SOURCE Rapha Capital Management, LLC and Ponce Therapeutics, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

Rapha Capital Management Leads Convertible Note Financing PR Newswire MIAMI, Feb. 8, 2021 \/PRNewswire\/ — Ponce Therapeutics, Inc. (“Ponce”), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, has now become operational with the launching of its first R & D program, targeting aging-associated skin disorders. The Company has secured laboratory space in Houston, TX, and has hired its first scientists for executing their R & D plan targeting the elimination of p16-expressing cells in the skin. The cell proliferation inhibitor, p16, is highly expressed in both senescent cells and in in situ carcinoma (Bowen’s Disease), which will be the focus of Ponce’s efforts for first product approval. Rapha Capital Management, LLC (https:\/\/www.raphacap.com), an … <\/p>\n

Continue reading “Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-430595","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPonce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Rapha Capital Management Leads Convertible Note Financing PR Newswire MIAMI, Feb. 8, 2021 \/PRNewswire\/ — Ponce Therapeutics, Inc. (“Ponce”), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, has now become operational with the launching of its first R & D program, targeting aging-associated skin disorders. The Company has secured laboratory space in Houston, TX, and has hired its first scientists for executing their R & D plan targeting the elimination of p16-expressing cells in the skin. The cell proliferation inhibitor, p16, is highly expressed in both senescent cells and in in situ carcinoma (Bowen’s Disease), which will be the focus of Ponce’s efforts for first product approval. Rapha Capital Management, LLC (https:\/\/www.raphacap.com), an … Continue reading "Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-08T13:33:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1432488\/image001_ID_28a7154e19a8.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin\",\"datePublished\":\"2021-02-08T13:33:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/\"},\"wordCount\":977,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1432488\\\/image001_ID_28a7154e19a8.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/\",\"name\":\"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1432488\\\/image001_ID_28a7154e19a8.jpg\",\"datePublished\":\"2021-02-08T13:33:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1432488\\\/image001_ID_28a7154e19a8.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1432488\\\/image001_ID_28a7154e19a8.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/","og_locale":"en_US","og_type":"article","og_title":"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin - Market Newsdesk","og_description":"Rapha Capital Management Leads Convertible Note Financing PR Newswire MIAMI, Feb. 8, 2021 \/PRNewswire\/ — Ponce Therapeutics, Inc. (“Ponce”), a company leveraging the growing scientific knowledge surrounding the aging process to develop anti-aging technologies, has now become operational with the launching of its first R & D program, targeting aging-associated skin disorders. The Company has secured laboratory space in Houston, TX, and has hired its first scientists for executing their R & D plan targeting the elimination of p16-expressing cells in the skin. The cell proliferation inhibitor, p16, is highly expressed in both senescent cells and in in situ carcinoma (Bowen’s Disease), which will be the focus of Ponce’s efforts for first product approval. Rapha Capital Management, LLC (https:\/\/www.raphacap.com), an … Continue reading \"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/","og_site_name":"Market Newsdesk","article_published_time":"2021-02-08T13:33:40+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1432488\/image001_ID_28a7154e19a8.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin","datePublished":"2021-02-08T13:33:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/"},"wordCount":977,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1432488\/image001_ID_28a7154e19a8.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/","name":"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1432488\/image001_ID_28a7154e19a8.jpg","datePublished":"2021-02-08T13:33:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1432488\/image001_ID_28a7154e19a8.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1432488\/image001_ID_28a7154e19a8.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ponce-therapeutics-inc-commences-first-r-d-program-in-anti-aging-products-for-skin\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ponce Therapeutics Inc. Commences First R & D Program in Anti-Aging Products for Skin"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/430595","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=430595"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/430595\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=430595"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=430595"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=430595"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}